New weapon tested against Tough-to-Treat blood cancer
NCT ID NCT06916767
Summary
This early-stage study is testing a new type of CAR-T cell therapy called LMY-920 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to standard treatments. The therapy uses the patient's own modified immune cells to target a protein called BAFF on cancer cells. The main goals are to find a safe dose and see if the treatment shows early signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
RECRUITINGCleveland, Ohio, 44195, United States
Contact
Conditions
Explore the condition pages connected to this study.